Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 286

The DOI matches its Crossref record; 280 of the 280 references it cites were found in a registry or an index.

Control of human toxoplasmosis

Open access
Smith, Nicholas C., Goulart, Cibelly, Hayward, Jenni A., Kupz, Andreas, Miller, Catherine M., van Dooren, Giel G.·2021·International Journal for Parasitology

Abstract

Toxoplasmosis is caused by Toxoplasma gondii, an apicomplexan parasite that is able to infect any nucleated cell in any warm-blooded animal. Toxoplasma gondii infects around 2 billion people and, whilst only a small percentage of infected people will suffer serious disease, the prevalence of the parasite makes it one of the most damaging zoonotic diseases in the world. Toxoplasmosis is a disease with multiple manifestations: it can cause a fatal encephalitis in immunosuppressed people; if first contracted during pregnancy, it can cause miscarriage or congenital defects in the neonate; and it can cause serious ocular disease, even in immunocompetent people. The disease has a complex epidemiology, being transmitted by ingestion of oocysts that are shed in the faeces of definitive feline hosts and contaminate water, soil and crops, or by consumption of intracellular cysts in undercooked meat from intermediate hosts. In this review we examine current and future approaches to control toxoplasmosis, which encompass a variety of measures that target different components of the life cycle of T. gondii. These include: education programs about the parasite and avoidance of contact with infectious stages; biosecurity and sanitation to ensure food and water safety; chemo- and immunotherapeutics to control active infections and disease; prophylactic options to prevent acquisition of infection by livestock and cyst formation in meat; and vaccines to prevent shedding of oocysts by definitive feline hosts.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ijpara.2020.11.001

Cites

280 of 280 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 280 references

Research works printed but not linked: 97

  1. Abdelbaset, 2017, Lactate dehydrogenase in Toxoplasma gondii controls virulence, bradyzoite differentiation, and chronic infection, PLoS ONE, 12, 10.1371/journal.pone.0173745 · doi:10.1371/journal.pone.0173745
  2. Adeyemi, 2018, Screening of chemical compound libraries identified new anti-Toxoplasma gondii agents, Parasitol. Res., 117, 355, 10.1007/s00436-017-5698-1 · doi:10.1007/s00436-017-5698-1
  3. Adeyemi, 2019, Nanoparticles show potential to retard bradyzoites in vitro formation of Toxoplasma gondii, Folia Parasitol., 66, 001, 10.14411/fp.2019.001 · doi:10.14411/fp.2019.001
  4. Alajmi, 2019, Anti-Toxoplasma activity of silver nanoparticles green synthesizes with Phoenix dactylifera and Ziziphus spina-christi extracts which inhibits inflammation through liver regulation of cytokines in Balb/c mice, Biosci. Rep., 39, 10.1042/BSR20190379 · doi:10.1042/bsr20190379
  5. Aly, 2018, Advantages of bioconjugated silica-coated nanoparticles as an innovative diagnosis for human toxoplasmosis, Acta Tropica, 177, 19, 10.1016/j.actatropica.2017.09.024 · doi:10.1016/j.actatropica.2017.09.024
  6. Amberg-Johnson, 2019, Host cell metabolism contributes to delayed-death kinetics of apicoplast inhibitors in Toxoplasma gondii, Antimicrob. Agents Chemother., 63, 10.1128/AAC.01646-18 · doi:10.1128/aac.01646-18
  7. Anand, 2015, Oral administration of encapsulated bovine lactoferrin nanocapsules against intracellular parasite Toxoplasma gondii, Int. J. Nanomed., 10, 6355
  8. Araujo, 1997, Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis, Antimicrob. Agents Chemother., 41, 188, 10.1128/AAC.41.1.188 · doi:10.1128/aac.41.1.188
  9. Araujo, 1992, In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii, Antimicrob. Agents Chemother., 36, 326, 10.1128/AAC.36.2.326 · doi:10.1128/aac.36.2.326
  10. Araujo, 1974, Effect of clindamycin on acute and chronic toxoplasmosis in mice, Antimicrob. Agents Chemother., 5, 647, 10.1128/AAC.5.6.647 · doi:10.1128/aac.5.6.647
  11. Baatz, 2006, Reactivation of Toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient, Ocular Immunol. Inflamm., 14, 185, 10.1080/09273940600659740 · doi:10.1080/09273940600659740
  12. Balaskas, 2012, Azithromycin versus sulfadiazine and pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study, Med. Sci. Monitor, 18, CR296, 10.12659/MSM.882735 · doi:10.12659/msm.882735
  13. Benedetto, 1991, Effect of rIFN-gamma and IL-2 treatments in mouse and nude rat infections with Toxoplasma gondii, Eur. Cytokine Netw., 2, 107
  14. Bhadra, 2012, IL-7 and IL-15 do not synergize during CD8 T cell recall response against an obligate intracellular parasite, Microbes Infect., 14, 1160, 10.1016/j.micinf.2012.07.018 · doi:10.1016/j.micinf.2012.07.018
  15. Bosch-Driessen, 2002, A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis, American J. Ophthalmol., 134, 34, 10.1016/S0002-9394(02)01537-4 · doi:10.1016/s0002-9394(02)01537-4
  16. Brenier-Pinchart, 2006, The Toxoplasma surface protein SAG1 triggers efficient in vitro secretion of chemokine ligand 2 (CCL2) from human fibroblasts, Microbes Infect., 8, 254, 10.1016/j.micinf.2005.06.023 · doi:10.1016/j.micinf.2005.06.023
  17. Buxton, 1994, Primary and secondary responses of the ovine lymph node to Toxoplasma gondii: cell output in efferent lymph and parasite detection, J. Comp. Pathol., 111, 231, 10.1016/S0021-9975(05)80002-7 · doi:10.1016/s0021-9975(05)80002-7
  18. Buyukbaba Boral, 2012, Investigation of combined effectiveness of spiramycin and beta-glucan in mice models of acute toxoplasmosis and determination of IL-10, IL-12 and TNF-alpha levels, Mikrobiyoloji bulteni, 46, 446
  19. Camps, 2002, An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii, Mol. Microbiol., 43, 1309, 10.1046/j.1365-2958.2002.02825.x · doi:10.1046/j.1365-2958.2002.02825.x
  20. Carellos, 2014, Adverse socioeconomic conditions and oocyst-related factors are associated with congenital toxoplasmosis in a population-based study in Minas Gerais, Brazil, PLoS One, 9, 10.1371/journal.pone.0088588 · doi:10.1371/journal.pone.0088588
  21. Choromanski, 1995, Safety and efficacy of modified live feline Toxoplasma gondii vaccine, Dev. Biol. Stand., 84, 269
  22. da Cunha, 2012, Humoral and cellular immune responses in pigs immunized intranasally with crude rhoptry proteins of Toxoplasma gondii plus Quil-A, Vet. Parasitol., 186, 216, 10.1016/j.vetpar.2011.11.034 · doi:10.1016/j.vetpar.2011.11.034
  23. Delemarre, 1994, Effect of IFN-gamma on the proliferation of Toxoplasma gondii in monocytes and monocyte-derived macrophages from AIDS patients, Immunology, 83, 646
  24. Delemarre, 1993, Restoration of the toxoplasmastatic activity of monocytes from AIDS patients during in vivo treatment with interferon-gamma, J. Infect. Dis., 168, 516, 10.1093/infdis/168.2.516 · doi:10.1093/infdis/168.2.516
  25. Doggett, 2020, Orally bioavailable endochin-like quinolone carbonate ester prodrug reduces Toxoplasma gondii brain cysts, Antimicrob. Agents Chemother., 64, e00535, 10.1128/AAC.00535-20 · doi:10.1128/aac.00535-20
  26. Dubey, 2017, Schizogony and gametogony of oocyst-deficient T-263 strain of Toxoplasma gondii, Vet. Parasitol., 245, 160, 10.1016/j.vetpar.2017.05.024 · doi:10.1016/j.vetpar.2017.05.024
  27. Dubey, 1994, Persistence of immunity to toxoplasmosis in pigs vaccinated with a nonpersistent strain of Toxoplasma gondii, Am. J. Vet. Res., 55, 982, 10.2460/ajvr.1994.55.07.982 · doi:10.2460/ajvr.1994.55.07.982
  28. Dubey, 1998, Immunity to toxoplasmosis in pigs fed irradiated Toxoplasma gondii oocysts, J. Parasitol., 84, 749, 10.2307/3284582 · doi:10.2307/3284582
  29. Dumas, 1994, Evaluation of the efficacy of prolonged administration of azithromycin in a murine model of chronic toxoplasmosis, J. Antimicrob. Chemother., 34, 111, 10.1093/jac/34.1.111 · doi:10.1093/jac/34.1.111
  30. Ferguson, 1994, An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii, Int. J. Exp. Pathol., 75, 111
  31. Frenkel, 1967, Adoptive immunity to intracellular infection, J. Immunol., 98, 1309, 10.4049/jimmunol.98.6.1309 · doi:10.4049/jimmunol.98.6.1309
  32. Freppel, 2019, Structure, composition, and roles of the Toxoplasma gondii oocyst and sporocyst walls, Cell Surf., 5, 10016, 10.1016/j.tcsw.2018.100016 · doi:10.1016/j.tcsw.2018.100016
  33. Freyre, 2007, Toxoplasma gondii: cross-immunity against the enteric cycle, Exp. Parasitol., 115, 48, 10.1016/j.exppara.2006.05.007 · doi:10.1016/j.exppara.2006.05.007
  34. Fu, 2011, Generation of a neutralizing human monoclonal antibody Fab fragment to surface antigen 1 of Toxoplasma gondii tachyzoites, Infect. Immun., 79, 512, 10.1128/IAI.00969-10 · doi:10.1128/iai.00969-10
  35. Gao, 2018, Immune response and protective effect against chronic Toxoplasma gondii infection induced by vaccination with a DNA vaccine encoding profilin, BMC Infect. Dis., 18, 117, 10.1186/s12879-018-3022-z · doi:10.1186/s12879-018-3022-z
  36. Gasparotto Junior, 2016, Effects of extracts from Echinacea purpurea (L) MOENCH on mice infected with different strains of Toxoplasma gondii, Parasitol. Res., 115, 3999, 10.1007/s00436-016-5167-2 · doi:10.1007/s00436-016-5167-2
  37. Hagras, 2019, Successful treatment of acute experimental toxoplasmosis by spiramycin-loaded chitosan nanoparticles, Exp. Parasitol., 204, 10.1016/j.exppara.2019.107717 · doi:10.1016/j.exppara.2019.107717
  38. Haverkos, 1987, Assessment of therapy for toxoplasma encephalitis. The TE Study Group, Am J. Med., 82, 907, 10.1016/0002-9343(87)90151-3 · doi:10.1016/0002-9343(87)90151-3
  39. Hegazy, 2015, Novel IMB-ELISA assay for rapid diagnosis of human toxoplasmosis using SAG-1 antigen, Jpn. J. Infect. Dis., 68, 474, 10.7883/yoken.JJID.2014.444 · doi:10.7883/yoken.jjid.2014.444
  40. Ivanetich, 1990, Thymidylate synthase-dihydrofolate reductase in protozoa, Exp. Parasitol., 70, 367, 10.1016/0014-4894(90)90119-W · doi:10.1016/0014-4894(90)90119-w
  41. Jiang, 2013, A novel immunosensor for detecting Toxoplasma gondii-specific IgM based on goldmag nanoparticles and graphene sheets, Colloids Surf., B Biointerfaces, 101, 481, 10.1016/j.colsurfb.2012.07.021 · doi:10.1016/j.colsurfb.2012.07.021
  42. Jiang, 2012, An agent-based model for the transmission dynamics of Toxoplasma gondii, J. Theoret. Biol., 293, 15, 10.1016/j.jtbi.2011.10.006 · doi:10.1016/j.jtbi.2011.10.006
  43. Kasper, 1995, IL-7 stimulates protective immunity in mice against the intracellular pathogen, Toxoplasma gondii, J. Immunol., 155, 4798, 10.4049/jimmunol.155.10.4798 · doi:10.4049/jimmunol.155.10.4798
  44. Katlama, 1996, Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group, AIDS, 10, 1107
  45. Kersten, 2019, Unexpected neurologic complications following a novel lymphoma treatment 'expected' to give rise to neurologic toxicity, BMJ Case Rep., 12, 10.1136/bcr-2019-229946 · doi:10.1136/bcr-2019-229946
  46. Keyhani, 2020, Biogenic selenium nanoparticles target chronic toxoplasmosis with minimal cytotoxicity in a mouse model, J. Med. Microbiol., 69, 104, 10.1099/jmm.0.001111 · doi:10.1099/jmm.0.001111
  47. Kim, 2007, Bradyzoite-specific surface antigen SRS9 plays a role in maintaining Toxoplasma gondii persistence in the brain and in host control of parasite replication in the intestine, Infect. Immun., 75, 1626, 10.1128/IAI.01862-06 · doi:10.1128/iai.01862-06
  48. Kochanowsky, 2020, A single transcription factor drives Toxoplasma gondii differentiation, Cell, 180, 216, 10.1016/j.cell.2019.12.038 · doi:10.1016/j.cell.2019.12.038
  49. Konrad, 2013, Inhibitors of eIF2α dephosphorylation slow replication and stabilize latency in Toxoplasma gondii, Antimicrob. Agents Chemoth., 57, 1815, 10.1128/AAC.01899-12 · doi:10.1128/aac.01899-12
  50. Liang, 2020, Acquisition of exogenous fatty acids renders apicoplast-based biosynthesis dispensable in tachyzoites of Toxoplasma, J. Biol. Chem., 295, 7743, 10.1074/jbc.RA120.013004 · doi:10.1074/jbc.ra120.013004
  51. Lieberman, 2004, Interleukin-15-deficient mice develop protective immunity to Toxoplasma gondii, Infect. Immun., 72, 6729, 10.1128/IAI.72.11.6729-6732.2004 · doi:10.1128/iai.72.11.6729-6732.2004
  52. Ling, 2007, The farnesyl-diphosphate/geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates, J. Biol. Chem., 282, 30804, 10.1074/jbc.M703178200 · doi:10.1074/jbc.m703178200
  53. Ling, 2005, Bisphosphonate inhibitors of Toxoplasma gondii growth: in vitro, QSAR, and in vivo investigations, J. Med. Chem., 48, 3130, 10.1021/jm040132t · doi:10.1021/jm040132t
  54. Long, 2016, Analysis of noncanonical calcium-dependent protein kinases in Toxoplasma gondii by targeted gene deletion using CRISPR/Cas9, Infect. Immun., 84, 1262, 10.1128/IAI.01173-15 · doi:10.1128/iai.01173-15
  55. Machala, 2015, Toxoplasmosis in immunocompromised patients, Epidemiol. Mikrobiol. Imunol., 64, 59
  56. Mareze, 2019, Socioeconomic vulnerability associated to Toxoplasma gondii exposure in southern Brazil, PLoS One, 14, 10.1371/journal.pone.0212375 · doi:10.1371/journal.pone.0212375
  57. Martin, 2001, Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy, J. Med. Chem., 44, 909, 10.1021/jm0002578 · doi:10.1021/jm0002578
  58. Martorelli Di Genova, 2019, Intestinal-delta-6-desaturase activity determines hots range for Toxoplasma sexual reproduction, PLoS Biol., 17, 10.1371/journal.pbio.3000364 · doi:10.1371/journal.pbio.3000364
  59. Martynowicz, 2020, Efficacy of guanabenz combination therapy against chronic toxoplasmosis across multiple mouse strains, Antimicrob. Agents Chemother., 10.1128/AAC.00539-20 · doi:10.1128/aac.00539-20
  60. Mateus-Pinilla, 2002, A computer simulation of the prevention of the transmission of Toxoplasma gondii on swine farms using a feline T. gondii vaccine, Prev. Vet. Med., 55, 17, 10.1016/S0167-5877(02)00057-0 · doi:10.1016/s0167-5877(02)00057-0
  61. McLeod, 2006, Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis, Pediatr. Infect. Dis. J., 25, 270, 10.1097/01.inf.0000202070.59190.9a · doi:10.1097/01.inf.0000202070.59190.9a
  62. McLeod, 2014, Management of congenital toxoplasmosis, Curr. Pediatr. Rep., 2, 166, 10.1007/s40124-014-0055-7 · doi:10.1007/s40124-014-0055-7
  63. Medawar-Aguilar, 2019, Serological diagnosis of toxoplasmosis disease using a fluorescent immunosensor with chitosan-ZnO-nanoparticles, Anal. Biochem., 564–565, 116, 10.1016/j.ab.2018.10.025 · doi:10.1016/j.ab.2018.10.025
  64. Megged, 2008, Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation, Pediatr. Transplant., 12, 902, 10.1111/j.1399-3046.2007.00891.x · doi:10.1111/j.1399-3046.2007.00891.x
  65. Mui, 2005, Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo, Antimicrob. Agents Chemother., 49, 3463, 10.1128/AAC.49.8.3463-3467.2005 · doi:10.1128/aac.49.8.3463-3467.2005
  66. Mui, 2008, Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo, PLoS Neglect. Trop. Dis., 2, 10.1371/journal.pntd.0000190 · doi:10.1371/journal.pntd.0000190
  67. Narasimhan, 2008, Translation regulation by eukaryotic initiation factor-2 kinases in the development of latent cysts in Toxoplasma gondii, J. Biol. Chem., 283, 16591, 10.1074/jbc.M800681200 · doi:10.1074/jbc.m800681200
  68. Nishimura, 2017, CCR5 Is involved in interruption of pregnancy in mice infected with Toxoplasma gondii during early pregnancy, Infect. Immun., 85, e00257, 10.1128/IAI.00257-17 · doi:10.1128/iai.00257-17
  69. Nogareda, 2014, Incidence and prevalence of Toxoplasma gondii infection in France, 1980–2020: model-based estimation, Epidemiol. Infect., 142, 1661, 10.1017/S0950268813002756 · doi:10.1017/s0950268813002756
  70. O'Connell, 1988, Toxoplasmosis in sheep. II. The ability of a live vaccine to prevent lamb losses after an intravenous challenge with Toxoplasma gondii, NZ Vet. J., 36, 1, 10.1080/00480169.1988.35461 · doi:10.1080/00480169.1988.35461
  71. Omata, 1996, Toxoplasma gondii: experimental infection in cats vaccinated with 60Co-irradiated tachyzoites, Vet. Parasitol., 65, 173, 10.1016/S0304-4017(96)00973-9 · doi:10.1016/s0304-4017(96)00973-9
  72. Pearson, 1999, Atovaquone for the treatment of Toxoplasma retinochoroiditis in immunocompetent patients, Ophthalmology, 106, 148, 10.1016/S0161-6420(99)90021-0 · doi:10.1016/s0161-6420(99)90021-0
  73. Pfefferkorn, 1993, Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate, J. Parasitol., 79, 559, 10.2307/3283383 · doi:10.2307/3283383
  74. Pfefferkorn, 1983, Toxoplasma gondii: genetic crosses reveal phenotypic suppression of hydroxyurea resistance by fluorodeoxyuridine resistance, Exp. Parasitol., 55, 207, 10.1016/0014-4894(83)90015-2 · doi:10.1016/0014-4894(83)90015-2
  75. Pfefferkorn, 1992, Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant, Antimicrob. Agents Chemother., 36, 1091, 10.1128/AAC.36.5.1091 · doi:10.1128/aac.36.5.1091
  76. Pott, 2013, Isolated cerebellar toxoplasmosis as a complication of HIV infection, Int. J. STD AIDS, 24, 70, 10.1258/ijsa.2012.012189 · doi:10.1258/ijsa.2012.012189
  77. Romand, 1993, In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii, Antimicrob. Agents Chemother., 37, 2371, 10.1128/AAC.37.11.2371 · doi:10.1128/aac.37.11.2371
  78. Rothova, 1998, Azithromycin for ocular toxoplasmosis, Br. J. Ophthalmol., 82, 1306, 10.1136/bjo.82.11.1306 · doi:10.1136/bjo.82.11.1306
  79. Serranti, 2011, Congenital toxoplasmosis treatment, Eur. Rev. Med. Pharmacol. Sci., 15, 193
  80. Shakibaie, 2020, Prophylactic effects of biogenic selenium nanoparticles on acute toxoplasmosis: an in vivo study, Ann. Med. Surg., 54, 85, 10.1016/j.amsu.2020.04.010 · doi:10.1016/j.amsu.2020.04.010
  81. Sharif, 2016, The efficacy of herbal medicines against Toxoplasma gondii during the last 3 decades: a systematic review, Can. J. Physiol. Pharmacol., 94, 1237, 10.1139/cjpp-2016-0039 · doi:10.1139/cjpp-2016-0039
  82. Shubar, 2008, A new combined flow-cytometry-based assay reveals excellent activity against Toxoplasma gondii and low toxicity of new bisphosphonates in vitro and in vivo, J. Antimicrob. Chemother., 61, 1110, 10.1093/jac/dkn047 · doi:10.1093/jac/dkn047
  83. Singh, 2014, Serologic prevalence of Toxoplasma gondii in Indian women of child bearing age and effects of social and environmental factors, PLoS Negl. Trop. Dis., 8, 10.1371/journal.pntd.0002737 · doi:10.1371/journal.pntd.0002737
  84. Sullivan, 2004, Parasite-specific eIF2 (eukaryotic initiation factor-2) kinase required for stress-induced translation control, Biochem. J., 380, 523, 10.1042/bj20040262 · doi:10.1042/bj20040262
  85. Suzuki, 1990, The effect of anti-IFN-gamma antibody on the protective effect of Lyt-2+ immune T cells against toxoplasmosis in mice, J. Immunol., 144, 1954, 10.4049/jimmunol.144.5.1954 · doi:10.4049/jimmunol.144.5.1954
  86. Tu, 2020, MAG2, a Toxoplasma gondii bradyzoite stage-specific cyst matrix protein, mSphere, 5, e00100, 10.1128/mSphere.00100-20 · doi:10.1128/msphere.00100-20
  87. Turner, 2013, Modeling effective transmission pathways and control of the worlds’ most successful parasite, Theor. Pop. Biol., 86, 50, 10.1016/j.tpb.2013.04.001 · doi:10.1016/j.tpb.2013.04.001
  88. Velázquez-Hernández, 2019, Knolwedge and practices regarding toxoplasmosis in housewives: a cross sectional study in a northern Mexican city, PLoS One, 14, 10.1371/journal.pone.0222094 · doi:10.1371/journal.pone.0222094
  89. Villegas, 2002, Susceptibility of interleukin-2-deficient mice to Toxoplasma gondii is associated with a defect in the production of gamma interferon, Infect. Immun., 70, 4757, 10.1128/IAI.70.9.4757-4761.2002 · doi:10.1128/iai.70.9.4757-4761.2002
  90. Waldeland, 1983, Temperature-sensitive mutants of Toxoplasma gondii: pathogenicity and persistence in mice, J. Parasitol., 69, 171, 10.2307/3281293 · doi:10.2307/3281293
  91. Walker, 2013, Sex and Eimeria: a molecular perspective, Parasitology, 140, 1701, 10.1017/S0031182013000838 · doi:10.1017/s0031182013000838
  92. Welsch, 2016, Discovery of potent and selective lLeads against Toxoplasma gondii dihydrofolate reductase via structure-based design, ACS Med. Chem. Lett., 7, 1124, 10.1021/acsmedchemlett.6b00328 · doi:10.1021/acsmedchemlett.6b00328
  93. Xu, 2013, DNA detection of Toxoplasma gondii with a magnetic molecular beacon probe via CdTe@Ni quantum dots as energy donor, J. Nanomater., 2013, 62, 10.1155/2013/473703 · doi:10.1155/2013/473703
  94. Yang, 2009, A quick and parallel analytical method based on quantum dots labeling for TORCH-related antibodies, Nanoscale Res. Lett., 4, 1469, 10.1007/s11671-009-9422-7 · doi:10.1007/s11671-009-9422-7
  95. Yardley, 2002, In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii, Antimicrob. Agents Chemother., 46, 929, 10.1128/AAC.46.3.929-931.2002 · doi:10.1128/aac.46.3.929-931.2002
  96. Zhang, 2014, Potent and selective inhibitors of CDPK1 from T. gondii and C. parvum based on a 5-aminopyrazole-4-carboxamide scaffold, ACS Med. Chem. Lett., 5, 40, 10.1021/ml400315s · doi:10.1021/ml400315s
  97. Zulpo, 2012, Oocyst shedding in cats vaccinated by the nasal and rectal routes with crude rhoptry proteins of Toxoplasma gondii, Exp. Parasitol., 131, 223, 10.1016/j.exppara.2012.04.006 · doi:10.1016/j.exppara.2012.04.006

Cited by

See all 286

Metadata

Authors
Smith, N. C., Goulart, C., Hayward, J. A., Kupz, A., Miller, C. M., & van Dooren, G. G.
Venue
International Journal for Parasitology
Publisher
Elsevier BV
Published
2021-02
Volume
51
Issue
2-3
Pages
95-121
ISSN
0020-7519 (ISSN-L)
OpenAlex
W3117286581
Cited by
286
References
280
FWCI
21.37
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • National Health and Medical Research Council
  • Australian Research Council

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Control of human toxoplasmosis. https://app.cochat.ai/papers/10.1016/j.ijpara.2020.11.001
The paper
Smith, N. C., Goulart, C., Hayward, J. A., Kupz, A., Miller, C. M., & van Dooren, G. G. (2021). Control of human toxoplasmosis. International Journal for Parasitology. https://doi.org/10.1016/j.ijpara.2020.11.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.